Risk factors of lower limb DVT and thrombosis risk assessment after breast cancer surgery
10.3969/j.issn.1000-8179.2017.23.819
- VernacularTitle:乳腺癌术后发生下肢深静脉血栓的危险因素及血栓风险评估
- Author:
WANG SHOUJUN
1
;
WANG SHUAIBING
;
WANG TONG
;
LU SU
;
WEI CHONGYI
;
ZHANG ZHENDONG
;
LIU HONG
Author Information
1. 天津医科大学肿瘤医院乳腺肿瘤二科
- Keywords:
breast cancer;
deep venous thrombosis;
risk factors;
risk assessment model
- From:
Chinese Journal of Clinical Oncology
2017;44(23):1199-1203
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the risk factors of breast cancer complicated with deep venous thrombosis (DVT) in lower limb and to explore the predictive significance of the thrombus risk assessment model for patients with breast cancer. Methods:A total of 703 patients with breast cancer in Tianjin Medical University Cancer Institute and Hospital who suffered from DVT after operation dur-ing January 2013 to June 2016 were retrospectively selected as the thrombosis group. A total of 706 cases for the control group were selected by systematic sampling. The risk factors of lower limb DVT after surgery were investigated. The predictive values of the Khora-na and Caprini thrombosis risk assessment models for these patients were also presented in this research. Results:Age, BMI≥30 kg/m2, diagnosis by excisional biopsy, neoadjuvant chemotherapy, operation time>2 h, lipoprotein a (Lpa)>475.5 mg/L, protein C (PC)<102.5%, blood coagulation factor-Ⅷ(F-Ⅷ)>129.8%, and D-Dimer (D-D)>289.99 ng/mL had statistical differences between in the two groups (P<0.05). Significant difference between the groups was found in the Caprini scores (P<0.001) but not in the Khorana thrombo-sis risk assessment model (P=0.207). Conclusion:Age, BMI≥30 kg/m2, diagnosis by excisional biopsy, neoadjuvant chemotherapy, op-eration time>2 h, Lpa>475.5 mg/L, PC<102.5%, F-Ⅷ>129.8%, and D-D>289.99 ng/mL are the independent risk factors of thrombo-sis. The Caprini thrombosis risk assessment model may require complicated evaluation. Hence, a new model that is suitable for pa-tients with breast cancer must be developed.
